SmartECG helps GPs diagnose heart conditions and get heart patients to treatment faster

SmartECG is a service for GPs and healthcare units that supports GPs in diagnosing heart patients.

SmartECG willl be ready for full scale market introduction in autumn 2018.

Read more on SmartECG Service >>

Cardiovascular Disease poses a serious health problem in the EU area and also globally.

Read more on why SmartECG Service is needed >>


SmartECG Service benefits patients, healthcare professionals and ECG device manufacturers

How can I get access to the SmartECG service?

Join SmartECG Panel for Healhcare Professionals

In the pre-piloting phase (approximately September 2017 to October 2018)

Your experience and insights as a healthcare professional are important in developing the SmartECG service. We therefore invite you to our SmartECG Panel for Healthcare Professionals. More information here.

In the piloting phase (approximately October to December 2018)

The pilot for the SmartECG service begins in late 2018, after clinical validation. The service will be available to healthcare clinics in Sweden using the Remote Diagnostic Service Platform provided by RemoteA Ab, and in the United Kingdom through RemoteA UK and our other partners.

Ask for a SmartECG Service demo

Would you like to see SmartECG Service in  a demonstration platfform? Please leave your contact information here and we will be in touch.

Subscribe to ECG Monitoring in the Future newsletter

Subscribe to our newsletter on ECG Monitoring in the Future here to stay up to date.

Follow us in LinkedIn ja Twitter

You can also follow us on LinkedIn and on Twitter in English and Finnish, and in Swedish


What is SmartECG?

Helps GPs diagnose heart conditions and get heart patients to treatment faster

With the SmartECG service, patients receive a secondary-care level diagnosis of their heart problems at the primary health care stage.

This earlier detection of heart diseases can lead to better treatment results, better quality of life, and even more lives saved.

Leads to faster and more cost-effective healthcare

The SmartECG service is a fast and cost-effective way of screening patients and referring them to secondary care when needed, as well as monitoring diagnosed heart patients through their illness and recovery in primary care.

Early detection of heart disease can lead to lower treatment costs.

SmartECG is a low-cost service.

Provides the GP with an automatic ECG analysis report within minutes

The report is available within minutes after the ECG data from an ECG monitoring device is loaded into the SmartECG service. The analysis is based on an algorithm i.e. artificial intelligence that automatically interprets ECG data, selects the most important results and supports GPs in making the diagnosis and treatment decisions.

The algorithm is based on a huge cardiological data bank (1.5 million hours of heart monitoring data of more than 90,000 patients) compiled by RemoteA Ltd.

In addition to the automatic analysis, the GP can get a cardiologist’s diagnosis either through the SmartECG service or from his/her own healthcare unit.





Easy to use

Healthcare professionals connect the monitoring device to the computer and upload ECG data to the SmartECG service

The automatic analysis report is delivered directly to the GP’s computer, laptop or mobile device within minutes

The automatic analysis report can also be automatically transferred to the patient data records

In the near future, ECG data will transfer automatically from the monitoring device to the SmartECG service


Flexible integration to healthcare processes

Healthcare units can choose how to integrate the SmartECG service into their clinical pathways that lead to a diagnosis. There are several options to integrate it:

  • The GP makes the diagnosis him/herself with the support of the SmartECG automatic analysis report
  • The GP requests a SmartECG specialist’s consultation report and receives it on average two days after downloading the ECG data
  • The GP chooses an internal specialist’s consultation, and data is automatically sent to the internal specialist for analysis

All in all, SmartECG supports clinical decision making and enhances co-operation between GPs and cardiologists

Compatible with most of ECG monitoring devices

SmatECG will be compatible with both rest and event monitoring devices

Healthcare clinics will be able to use it with their existing ECG monitoring devices, which can thus be put to a more efficient use

In the piloting phase in 2018, the SmartECG service will provide automatic analysis reports from Holter monitoring devices

Compatibility will be further developed in co-operation with ECG device manufacturers

By 2020, the SmartECG service will analyse ECG data from virtually any ECG monitoring device


Medically validated

The SmartECG service will be a medically validated tool for healthcare by the CE and FDA

The validation process will start in the spring of 2018 and the piloting phase is expected to start in the autumn of 2018

Why is SmartECG developed

Cardiovascular Disease poses a serious health problem in the EU area and also globally.

  • Almost 10 % of EU population is affected by CVD.
  • In total almost 49 million people have been diagnosed in EU.
  • In total over 85 million people have been diagnosed in Europe.
  • In EU over 6 million people were diagnosed with CVD in 2015.
  • In Europe over 11 million people were diagnosed with CVD in 2015.
  • CVD is the number one cause of death in most European countries.
  • CVD or CVD-related diseases account for 37 % of deaths in EU (1.8 million people annually) and 45 % of deaths in Europe (3.9 million people annully)
  • Early deaths (under 75 years old): In EU over 400.000 early deaths meaning 26 % of all early deaths, stroke-related deaths account for 59 % of deaths.
  • In Europe over 1.3 million meaning 35 % of all early deaths. Stroke-related deaths account for 51 % of deaths and ischemic heart disease for 49 %.
  • Total CVD costs were 110 billion euros in EU countries 110 billion euros (2015).
  • Costs per capita is EU €218
  • Of CVD costs 51 % is spent in inpatient care and 9 % in primary care.
  • Interpreting the ECG analysis results causes a bottleneck in the primary care level as GPs are not equipped to interpret first ECG analysis results by themselves, and in the secondary care level, as specialist cardiologists are facing a huge data and work overload.
  • In Finland CVD is the fourth most general reason to visit doctor’s appointment (after musculoskeletal and respiratory diseases). It also causes multiple visits: there were on average 5 visits per person to nurse appointment due to palpitations *
  • Today 8 million tests performed annually in Europe, estimated to grow to 11 million analyses by 2020 (due to advancements in patient-friendly analysis tools and increased number of CVD patients).
  • Global ECG management systems market will grow to €180 million by 2020. **

The direct impacts and their related effects from SmartECG are:

  1. Better treatment of cardiovascular diseases

  • More accurate and faster diagnosis by more comprehensive and detailed ECG analysis
  • Lower mortality rate and increased life-expectancy of CVD patients
  1. Increased patient-friendliness

  • Reduced healthcare waiting times, increased accessibility to specialist care
  • Wider implementation of remote (home-) monitoring practices
  • Reduced travel costs and time
  1. Higher medical professionality

  • Empowered primary and secondary care specialists in CVD diagnosing and monitoring
  • Increased collaboration and sharing practices between GPs and specialist physicians
  1. More efficient healthcare system

  • Improved and more competent primary care level
  • Shorter waiting lists, increased patients throughput
  • Lower cost per patient and reduced CVD treatment expenditures
  • Increased international cooperation and free movement of healthcare services in EU
  • Standardised ECG analysis output for best compatibility with various eHealth solutions



We are happy to tell you more about SmartECG service

Please contact:

Mr. Heikki Väänänen, Head of Anaytics, heikki.vaananen(at), tel. +358 50 586 7460

Ms. Hannele Pulliainen, Marketing Manager, hannele.pulliainen(at), tel. +358 44 355 5225

Press release 7.3.2017

Press release 17.10.2017

Lehdistötiedote 7.3.2017

Lehdistötiedote 17.10.2017



SmartECG is co-funded by the Horizon 2020 programme that helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition.

RemoteA Ltd. was one of the four ICT companies to receive funding of the total 104 ICT companies applying for it, and RemoteA Ltd. also received the highest scores.